Recent Developments

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Holdings Names Eric Hipkins Chief Executive Officer

root9B Holdings, Inc. (Nasdaq: RTNB) (“RTNB”), a leading provider of Cybersecurity and Regulatory Risk Mitigation Services, today announced that its Board of Directors has appointed Eric Hipkins as Chief Executive Officer effective May 25, 2017.

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave

ContraFect Corporation (NASDAQ: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chief Executive Officer and Chairman of … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today recent progress and financial results for the three and twelve months ended December 31, 2016.

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics to Present at Cowen and Company 37th Annual Healthcare Conference on March 8, 2017

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Brian A. Leuthner, President and Chief Executive Officer, will make a corporate presentation at Cowen and Company’s 37th … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Remains #1 on the Cybersecurity 500 For 5th Consecutive Quarter

In response to remaining #1 on the Cybersecurity 500 for Q1 2017, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “root9B is extremely proud to remain as the #1 company on the Cybersecurity 500 for the fifth consecutive … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Holdings to Participate in 29th Annual ROTH Conference

root9B Holdings, Inc. (NASDAQ: RTNB) (“Company”) today announced that it will attend the 29th Annual ROTH Conference in Dana Point, CA. The Company’s management will conduct one-on-one meetings with interested investors throughout the day on Monday, March 13, 2017 and … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial results and corporate highlights for the fourth quarter and full-year ended December 31, 2016.

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the Cowen and … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics Announces Conference Call on March 2, 2017 to Discuss Fourth Quarter and Full Year 2016 Financial Results

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that it will host a conference call on Thursday, March 2, 2017 at 8:30 a.m. ET to discuss its … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children’s Hospital of Philadelphia

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia (CHOP). The amendment to … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off